Recent Advances in Glucocorticoid Receptor Action - Cato, A. / Schaecke, H. / Asadullah, K. (eds.)
Bisher 209,99 €**
205,99 €
versandkostenfrei*

inkl. MwSt.
**Früherer Preis
Sofort lieferbar
103 °P sammeln
    Gebundenes Buch

Since 1948, hydrocortisone (cortisol), the principal glucocorticoid (GC) of the human adrenal cortex has been successfully used at phar macological concentrations for the suppression of clinical manifesta tions of rheumatoid arthritis. Numerous compounds with GC activity have also been developed and used. Fifty years after their initial clinical use, GCs are still the most im portant and frequently prescribed class of anti-inflammatory drugs for various inflammatory disorders. They are administered either orally, parenterally (intravenous, intramuscular, intrathecal), or topically (cu taneous,…mehr

Produktbeschreibung
Since 1948, hydrocortisone (cortisol), the principal glucocorticoid (GC) of the human adrenal cortex has been successfully used at phar macological concentrations for the suppression of clinical manifesta tions of rheumatoid arthritis. Numerous compounds with GC activity have also been developed and used. Fifty years after their initial clinical use, GCs are still the most im portant and frequently prescribed class of anti-inflammatory drugs for various inflammatory disorders. They are administered either orally, parenterally (intravenous, intramuscular, intrathecal), or topically (cu taneous, intranasal, pulmonic, rectal). Despite the many beneficial ef fects of GCs, they also have their limitations and disadvantages that occur with varying prevalence on different organs and after different durations of therapy. These side-effects can range in severity from cos metic (e.g. telangiectasias, hypertrichosis) to seriously disabling (e.g. induction of glaucoma, diabetes, osteoporosis) or even life-threatening disorders (e.g. gastric haemorrhage). These adverse effects of GCs se riously handicap their successful use as anti-inflammatory agents. There is therefore a strong need for the development of substances with the anti-inflammatory potency of classical GCs but with reduced side-effects.
  • Produktdetails
  • Ernst Schering Research Foundation Workshop Vol.40
  • Verlag: Springer, Berlin
  • Artikelnr. des Verlages: 10866377
  • 2002
  • Seitenzahl: 408
  • Erscheinungstermin: 12. September 2002
  • Englisch
  • Abmessung: 235mm x 157mm x 29mm
  • Gewicht: 684g
  • ISBN-13: 9783540432296
  • ISBN-10: 3540432299
  • Artikelnr.: 10961553
Autorenporträt
A. Cato, Forschungszentrum Karlsruhe / H. Schaecke, Schering AG, Berlin / K. Asadullah, Schering AG, Berlin
Inhaltsangabe
P.J. Barnes: Glucocorticoids and Asthma; H.-D. Volk: Immunomonitoring of GC Therapy; W.Sterry and K. Asadullah: Topical GC Therapy in Dermatology;H.K. Väänänen and P.L. Härkönen: Bone Effects of GC Therapy; U.Pleyer and Z. Sherif: Corticosteroids in Ophtalmology; U.Wahn: Special Problems in GC Treatment of Children; D.D. DeFranco: Functional Implications of GC Receptor Trafficking;G.L.Hager: The Dynamics of Intranuclear Movement of Chromatin Remodeling by the GC Receptor; C. Caelles et al.: GC Receptor Anatgonism of AP-1 Activity by Inhibition of MAPK Family; O. Kassel and A.C.B. Cato: Mast Cells as Targets for GC in the Treatment of Allergic Disorders;A.-C. Wikström et al.: Cytosolic GC Receptor Interacting Proteins; M.J.M. Schaaf and J.A. Cidlowski: The GC Receptor ß-isoform: A Perspective on its Relevance in Human Health and Disease; B. Groner and C. Shemanko:. Cooperation of Nuclear Transcription Factors Regulated by Steroid and Peptide Hormones; W. Vanden Berghe et al.: Induction and Repression of NF-kB-driven Inflammatory Genes; A. Dostert and T. Heinzel: DNA-dependent Cofactor Selectivity of the GC Receptor; P. Herrlich: Cofactor Requirement for Transcriptional Crosstalk between the GC Receptor and Other Transcription Factors; C.Kellendonk et al.; X Analysis of GC Receptor Function by Gene Targeting Analysis in the Mouse; P. Mittelstadt et al.: Glucocorticoid-inducible Genes that Regulate T-Cell Function; U. Egner: Structural Analysis of the GR Ligand-binding Domain; H. Schäcke et al.: Selective GC Receptor Agonists (SEGRAs): A Novel Class of Antiinflammatory Compounds;